KURA Kura Oncology, Inc.

Overview and Growth

In fiscal 2025, Kura Oncology, Inc. recorded $67.48M of revenue, net loss of $278.67M, and an operating cash outflow of $64.06M. The $67.48M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. Compared with $53.88M in fiscal 2024, revenue recorded a 25.2% year-over-year increase. The company reported diluted EPS of -$3.18, adding a shareholder-level measure to the absolute income figures considered below. Total assets stood at $738.36M, showing the scale of resources supporting revenue, earnings, liquidity, and financing. Asset turnover was 0.09x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

Operations produced a $303.63M operating loss before non-operating and tax effects. The operating loss equaled 449.9% of revenue, showing the scale of the operating deficit relative to sales. After all below-operating-line items, the company recorded a net loss of $278.67M for the fiscal year. The net loss equaled 412.9% of revenue, showing the bottom-line deficit relative to the company’s sales base. Negative EBITDA totaled $302.60M, confirming that the earnings deficit remained before depreciation and amortization. The pretax result was a loss of $278.37M, establishing the deficit before tax effects. The pretax loss equaled 412.5% of revenue, measuring the pre-tax deficit against sales. The reported income-tax provision was $297.00K, the amount recognized between pretax income and the final net-income result. Relative to period-end equity, the net loss represented 160.0%. The loss-to-assets relationship was 37.7%, placing the bottom-line deficit against the company’s resource base. The bottom-line deficit increased from $173.98M in fiscal 2024 to $278.67M.

Liquidity and Capital Structure

At period end, the $738.36M asset base was financed through $564.23M of liabilities and $174.13M of equity. At period end, current assets of $708.66M compared with current liabilities of $116.97M, defining the company’s short-term resource position. Current assets covered current liabilities by 6.06x, leaving a positive buffer for near-term obligations. Reported cash and equivalents were $149.10M, separating immediately recognizable cash resources from the rest of the current-asset base. The cash balance equaled 127.5% of current liabilities, showing how much near-term coverage came from cash alone. The company carried $9.71M of total debt at period end, which frames its leverage and debt-service burden. The debt-to-equity relationship was 0.06x, showing how much debt the company carried for each unit of book equity. Relative to total assets, debt measured 1.3%, showing how much of the asset base was matched by borrowing. The equity-to-assets relationship was 23.6%, placing book capital against the total resource base. Liabilities represented 76.4% of total assets, quantifying the liability-funded share of the company’s resource base. Measured against total assets, cash and equivalents represented 20.2%, a balance-sheet composition measure rather than a liquidity forecast. Total assets were 2.9% lower than fiscal 2024 assets of $760.16M, measuring the company’s own balance-sheet change. Book equity was 57.9% lower than fiscal 2024 equity of $413.64M, showing how shareholder capital changed year over year. Cash and equivalents were 33.6% lower than fiscal 2024 cash of $224.46M, showing the year-over-year change in liquid resources.

Cash Flow and Earnings Quality

Operating activities used $64.06M of cash, resulting in an operating cash outflow for the year. Capital spending of $6.64M added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. The company recorded a $70.70M cash deficit after capital spending for the period. Free-cash-flow margin was -104.8%, reflecting a cash deficit equal to 104.8% of revenue after capital spending. Relative to total assets, the post-investment cash deficit measured 9.6%.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Sep 24, 2026.